Free Trial
OTCMKTS:INBP

Integrated BioPharma (INBP) Stock Price, News & Analysis

Integrated BioPharma logo
$0.30 +0.02 (+5.85%)
As of 09/23/2025 03:58 PM Eastern

About Integrated BioPharma Stock (OTCMKTS:INBP)

Advanced

Key Stats

Today's Range
$0.28
$0.33
50-Day Range
$0.26
$0.32
52-Week Range
$0.22
$0.42
Volume
35,540 shs
Average Volume
7,371 shs
Market Capitalization
$9.25 million
P/E Ratio
7.47
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive INBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integrated BioPharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INBP Stock News Headlines

INBP Integrated BioPharma, Inc.
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
Integrated Biopharma Inc (INBP)
Integrated BioPharma, Inc. (INBP)
See More Headlines

INBP Stock Analysis - Frequently Asked Questions

Integrated BioPharma's stock was trading at $0.3297 at the start of the year. Since then, INBP stock has decreased by 9.4% and is now trading at $0.2986.

Integrated BioPharma Inc. (OTCMKTS:INBP) posted its quarterly earnings data on Tuesday, September, 23rd. The company reported ($0.01) EPS for the quarter. Integrated BioPharma had a net margin of 2.37% and a trailing twelve-month return on equity of 6.36%.

Shares of INBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Integrated BioPharma investors own include GSK (GSK), Invitae (NVTA), Exxon Mobil (XOM), Autodesk (ADSK), Adaptive Biotechnologies (ADPT), Analog Devices (ADI) and Adaptimmune Therapeutics (ADAP).

Company Calendar

Last Earnings
5/14/2025
Today
9/23/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
6/30/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:INBP
CIK
1016504
Employees
150
Year Founded
1995

Profitability

EPS (Trailing Twelve Months)
$0.04
Trailing P/E Ratio
7.00
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$110 thousand
Net Margins
2.37%
Pretax Margin
3.55%
Return on Equity
6.36%
Return on Assets
4.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.72
Quick Ratio
1.70

Sales & Book Value

Annual Sales
$50.32 million
Price / Sales
0.17
Cash Flow
$0.04 per share
Price / Cash Flow
6.37
Book Value
$0.64 per share
Price / Book
0.44

Miscellaneous

Outstanding Shares
30,975,000
Free Float
10,160,000
Market Cap
$8.67 million
Optionable
Not Optionable
Beta
0.86

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (OTCMKTS:INBP) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners